In this study, we tested whether TLR4 signaling promotes a proinflammatory phenotype in human and mouse arterial smooth muscle cells (SMC), characterized by increased cytokine and chemokine synthesis and increased TLR expression. Human arterial SMC were found to express mRNA encoding TLR4 and the TLR4-associated molecules MD-2 and CD14 but not TLR2 mRNA. Mouse aortic SMC, on the other hand, expressed both TLR2 and TLR4 mRNA constitutively. Human SMC derived from the coronary artery, but not those from the pulmonary artery, were found to express cell surface-associated CD14. Low concentrations (ng/ml) of Escherichia coli LPS, the prototypical TLR4 agonist, markedly stimulated extracellular regulated kinase 1/2 (ERK1/2) activity, induced release of monocyte-chemoattractant protein-1 (MCP-1) and interleukin (IL)-6, and stimulated IL-1␣ expression in human aortic SMC, and exogenous CD14 enhanced these effects. Expression of a dominant negative form of TLR4 in human SMC attenuated LPS-induced ERK1/2 and MCP-1 release. LPS was a potent inducer of NF-B activity, ERK1/2 phosphorylation, MCP-1 release, and TLR2 mRNA expression in wild-type mice but not in TLR4-signaling deficient mouse aortic SMC. These studies show that TLR4 signaling promotes a proinflammatory phenotype in vascular smooth muscle cells (VSMC) and suggest that VSMC may potentially play an active role in vascular inflammation via the release of chemokines, proinflammatory cytokines, and increased expression of TLR2.
ATHEROSCLEROSIS is a chronic inflammatory disease, characterized during its early stages by monocyte invasion into the subendothelial space of the arterial wall and promoted by hypercholesterolemia (34) . Evidence that chronic infection may also contribute to vascular inflammation, although controversial, continues to accumulate. For example, microbes including the intracellular bacterium Chlamydia pneumoniae are present in the vessel wall (39) , where they could directly promote inflammation by direct activation of resident cells, including macrophages, endothelial cells, and vascular smooth muscle cells (VSMC). However, the pathological significance of exogenous pathogens and endogenous proinflammatory pathways and the specific roles of all participating cell types in human atherogenesis remain the subjects of intensive research.
Microbial pathogens activate immune cells by mechanisms involving the engagement of Toll-like receptors (TLRs), a family of transmembrane receptors that are expressed in a cell-type specific manner and are activated by distinct pathogen-associated molecular patterns (PAMPs). Each TLR is characterized by an extracellular domain consisting of leucinerich repeats that confer specificity to particular PAMPs and by an intracellular domain sharing homology with the type I interleukin-1 (IL-1) receptor. Among the TLRs, TLR4 is a mediator of cellular activation by LPS derived from enterobacteria such as Escherichia coli. Activation of most TLRs, including TLR4, initiates recruitment of the adaptor molecule MyD88 to the intracellular domain of the receptor, leading to activation of the transcription factor NF-B and the production of proinflammatory cytokines and chemokines. Recent studies have suggested that TLR4 activation also plays a role in hypercholesterolemia-induced arterial inflammation in mice, as a deficiency of either TLR4 or the TLR adaptor protein MyD88 reduces monocyte recruitment to the vessel wall and lesion formation in apolipoprotein E-deficient (ApoEϪ/Ϫ) mice (5, 26) . The role of endogenous host-versus exogenous pathogenderived molecules in TLR4 activation in the setting of hypercholesterolemia and the role of TLR expression in various cell types remain to be determined.
With the consideration of the putative contributions of inflammatory pathways to atherogenesis, the presence of functional TLRs in VSMC may have fundamental significance in vascular pathology. Exposure to E. coli LPS is known to induce proinflammatory cytokine expression in human VSMC (23) . However, because early studies used relatively high concentrations (g/ml) of commercial LPS preparations that are now known to contain bioactive protein contaminants at levels sufficient to activate TLR2 (17, 41) , it is possible that TLR2 activation contributed to the observed effects. Recent findings indicate that functional TLR4 may be present in VSMC because these cells express TLR4 protein (36, 38) and respond to low levels (ng/ml) of LPS (38) , similar to human monocytes and macrophages, which are regarded as sentinels of the immune system. However, even low levels of commercial LPS preparations can stimulate TLR2 (17, 21, 41, 50) , and it has yet to be shown directly whether TLR4 mediates LPS actions in VSMC by using approaches that involve specific disruption of TLR4 signaling. In addition, a sensitive TLR4 signaling system in monocytes and macrophages requires the expression of critical coreceptor proteins CD14 and MD-2, in addition to TLR4 itself (27) . Accordingly, in the present study we tested whether human VSMC express TLR2, TLR4, CD14, and MD-2. We also used smooth muscle cells (SMC) from TLR2 and TLR4 signaling-deficient mice and recombinant adenoviral constructs expressing dominant negative TLR4 to test whether low concentrations (ng/ml) of highly purified E. coli LPS activate TLR4 in VSMC, leading to the release of proinflammatory cytokines and chemokines, indicative of a functional proinflammatory phenotype.
METHODS
SMC culture. Human SMC were cultured in smooth muscle growth medium 2 as recommended by the manufacturer (Clonetics) and used at passages 4 -9. SMC were isolated from the aorta of TLR4 wild-type (C3H/OuJ), TLR4 signaling-deficient (C3H/HeJ), TLR2ϩ/ϩ (C57BL/6), and TLR2Ϫ/Ϫ mice as previously described (40) . Mouse aortic SMC stained positive for smooth muscle ␣-actin and were used at passages 3-10. C3H/HeJ mice harbor a single-point mutation within the TLR4 gene encoding histidine rather than proline at position 712 within the signaling domain, resulting in the expression of a dominant negative receptor (30, 47) .
Recombinant adenovirus expressing dominant negative TLR4. An expression plasmid containing coding sequence for human TLR4 (1-700), but lacking amino acids 701-839 of the intracellular signaling domain, was obtained from Dr. Michael F. Smith, Jr. (University of Virginia, Charlottesville, VA) (37) . The truncated TLR4 insert was cut from the plasmid with Hind III and Xba I and cloned into a pCMV shuttle vector. The recombinant plasmid was linearized with PmeI and cotransformed into E. coli strain BJ5183 together with pAdEasy-1. Recombinants were selected with kanamycin and screened by restriction enzyme analysis. The recombinant adenoviral construct, which is E1 and E3 deleted, was then cleaved with PacI to expose its inverted terminal repeats and transfected into human embryonic kidney cell line 293 (HEK293) to produce viral particles. Adenovirus expressing mouse Pro712His TLR4 was obtained from the Program of Excellence in Gene Therapy (Pittsburgh, PA).
RT-PCR analysis. Total RNA was isolated from VSMC using an RNeasy kit (Qiagen) and treated with DNase I. RNA (1 g) was reverse transcribed with Moloney murine leukemia virus reverse transcriptase and amplified with Taq DNA polymerase by using human TLR2, TLR4, and ␤-actin primers as previously described (36) . CD14 primers (5Ј-GGAACTGACGCTCGAGGACCTAAAGATAAC-3Ј and 5Ј-TCCA-GCCCAGCGAACGACAGATTGAG-3Ј) yielded a 510-bp fragment. MD-2 primers (5Ј-GAAGCTCAGAAGCAGTATTGGGTC-3Ј and 5Ј-GGTTGGTGTAGGATGACAAACTCC-3Ј) yielded a 422-bp fragment. Primers were annealed at 55°C, and samples were amplified for 30 cycles.
Mouse TLR2 and TLR4 mRNA levels were analyzed by real-time PCR. For TLR2 mRNA analysis, cDNA was analyzed in triplicate by using SYBR Green PCR Master Mix (Applied Biosystems), 200 nM each of forward (AATTGCATCACCGGTCAGAAA) and reverse (GTTTGCTGAAGAGGACTGTTATGG) primer, 60°C annealing temperature, and ABI 7700 Sequence Detector. Taqman primers and probes (Assays on Demand; Applied Biosystems) were used to quantitate TLR4 mRNA levels. Each cDNA was analyzed with target gene and 18S rRNA primer sets that approached 100% amplification efficiency, allowing direct comparison of threshold cycle (Ct) values to determine relative gene expression. The target gene signal was first normalized to 18S rRNA signal and then expressed relative to the value obtained with control SMC by using the formula 2
Ϫ⌬⌬Ct .
Flow cytometric analysis. Human VSMC (0.5-1 ϫ 10 6 ) were deprived of serum for 48 h, detached from the culture dish with trypsin (0.025%, 2 min), washed, and incubated with phycoerythrin (PE)-conjugated mouse anti-human CD14 antibody or PE-conjugated isotype control antibody (mouse IgG2a,) at 4°C, for 90 min. VSMC were then washed, resuspended in PBS, and analyzed for intensity of PE fluorescence in a FACSCalibur flow cytometer (Becton Dickinson). Chinese hamster ovary cells stably expressing high levels of CD14 (10) were analyzed for comparison.
ELISA. Mouse aortic and human SMC were plated in 48-well plates (10,000 cells/well and 25,000 cells/well, respectively). Human SMC were deprived of serum (1% FCS, 72 h) and incubated for 6 h in serum-free media with or without human recombinant CD14 (100 ng/ml; R&D Systems) or E. coli serotype 0111:B4 LPS (Sigma), which had been repurified by phenol extraction (17) . The repurified LPS preparation had no detectable activity on HEK293 cells stably expressing TLR2. Mouse SMC were deprived of serum (1% FCS, 24 h) and incubated for 6 h in media with 0.25% FCS with or without LPS or CD14. Cell supernatants were analyzed by using specific ELISAs for mouse and human monocyte chemoattractant protein 1 (MCP-1) (BD Biosciences and R&D Systems, respectively) and human IL-6 (Cayman Chemical). Human SMC were lysed in buffer for analysis of cell-associated IL-1␣ (Cayman Chemical) (2) .
ERK1/2 activation. Mouse and human SMC were deprived of serum (0.25% FCS, 48 h). LPS, CD14, or both were then added, and the cells were incubated for 30 min and rapidly frozen in liquid nitrogen, and whole cell lysates were prepared as previously described (36) . Cellular protein (30 g) was separated on SDS-polyacrylamide gels, transferred to nitrocellulose membranes, and blotted with rabbit antibodies that detect either dually phosphorylated ERK1/2 (Thr202/ Tyr204) or total ERK1/2 (Cell Signaling Technology).
NF-B activation. Mouse aortic SMC were transfected by electroporation (220 V, 950 F) with a luciferase reporter plasmid containing 5 NF-B sites upstream of the firefly luciferase coding region (pNF-B-luc; Stratagene), plated (100,000 cells/well in 12-well plates), and incubated for 6 h in growth media containing 5 mM sodium butyrate. SMC were deprived of serum (1% FCS, 72 h) and then incubated for 6 h in fresh media with or without LPS or CD14 (100 ng/ml each).
EMSA. Mouse aortic SMC were deprived of serum (0.25% FCS, 24 h) and then stimulated with LPS and CD14 (100 ng/ml each) for various time points, and nuclear extracts were prepared as previously described (35) . Nuclear proteins (8 g) were preincubated in binding buffer containing 32 P-labeled consensus oligonucleotide (AGTT-GAGGGGACTTTCCCAGG; Promega) with or without a 25-fold excess of cold competitor oligonucleotide, and oligonucleotide-protein complexes resolved on a nondenaturing acrylamide gel (35) .
RESULTS

Human SMC express TLR4, MD-2, and CD14 mRNA.
In earlier studies, we found that human saphenous vein SMC express TLR4 mRNA and protein but not TLR2 (36) . Here, RT-PCR analysis indicated that human arterial SMC, derived from either pulmonary, aorta, or coronary arteries, express TLR4 mRNA at levels comparable to those in human monocytes but do not express TLR2 mRNA ( Fig. 1 ; data not shown). Because efficient activation of TLR4 by LPS requires the additional presence of CD14 and MD-2, which are believed to act in concert to deliver LPS to its active site in the TLR4 receptor complex (18, 46) , we also tested for expression of these genes in VSMC. RT-PCR analysis with the use of specific primers showed that human SMC express both CD14 and MD-2 mRNA (Fig. 1) . MD-2 mRNA was expressed at levels similar to or higher than those observed in human monocytes, whereas CD14 mRNA was expressed at variable levels that were lower than that of human monocytes. The observed expression of TLR4, MD-2, and CD14 mRNAs suggests that human SMC may synthesize three key receptor components that are essential to LPS signaling via TLR4.
Human SMC express cell surface CD14. Flow cytometric analysis revealed abundant cell surface CD14 expression in human coronary artery SMC (HCoASMC; passage 5; Fig. 2 ). Expression of CD14 could not be analyzed at earlier passages because insufficient numbers of cells were available. Most cells in this population were found to express CD14, some at levels similar to that of Chinese hamster ovary cells that stably express high levels of human CD14 and others at somewhat lower levels. In contrast with HCoASMC, in human pulmonary artery SMC (HPASMC; passage 5), cell surface CD14 was undetectable, indicating that CD14 expression is not consistent among different human arterial SMC preparations.
Exogenous CD14 enhances LPS-induced MCP-1 and IL-6 release and IL-1␣ synthesis.
Preliminary studies showed that treatment with LPS alone stimulated MCP-1 release in some, but not all, human SMC. Considering that some human VSMC do not express detectable CD14 (Fig. 2) and that soluble forms of CD14 can substitute for membrane-bound CD14 to enhance LPS responses in endothelial cells (15, 32) , we tested the ability of exogenous CD14 to enhance LPS responsiveness in human SMC. In HCoASMC, the addition of human recombinant CD14 enhanced responsiveness to LPS. Exposure to LPS alone (10 ng/ml) significantly stimulated both MCP-1 and IL-6 release, whereas addition of CD14 (100 ng/ml) markedly potentiated LPS-induced release of both cytokines (Fig. 3, A  and B) . IL-1␣ is a potent autocrine stimulator of SMC proliferation that remains primarily cell associated with low levels released by the cells (2) . Cell-associated IL-1␣ was not detectable in HCoASMC incubated with LPS or medium alone but was detectable in VSMC stimulated with LPS and CD14 (Fig.  3C) . In human aortic SMC, CD14 alone did not affect MCP-1 release in the absence of LPS but enhanced MCP-1 release induced by LPS (1-100 ng/ml), and the stimulatory effect of CD14 was most pronounced at a subthreshold LPS concentration (1 ng/ml) (Fig. 3D) .
Role of TLR4 in LPS-induced MCP-1 release and ERK activation in human SMC.
To assess the functional role of TLR4 in mediating LPS-induced MCP-1 release in HCoASMC, we used recombinant adenovirus engineered to express a dominant negative form of mouse TLR4. LPS and CD14 markedly stimulated MCP-1 release in HCoASMC incubated with a control adenovirus that expresses green fluorescent protein (Fig. 4A) , and the effect of LPS was significantly inhibited in HCoASMC infected with adenovirus expressing dominant negative mouse TLR4.
The protein kinase ERK1/2 is thought to play a role in the regulation of MCP-1 gene expression (9) , and it is activated by TLR4 in some cell types. LPS and CD14 activated ERK1/2 in HPASMC infected with empty adenovirus vector (Ad5-CMV; Fig. 4B ). In contrast, infection of HPASMC with adenovirus expressing dominant negative human TLR4 completely pre- vented LPS-stimulated ERK1/2 activation, supporting a role of TLR4 in LPS-induced ERK1/2 activity (Fig. 4B) .
Mouse aortic SMC express TLR2 and TLR4 mRNA. Unlike human SMC, mouse aortic SMC were found to constitutively express mRNA encoding TLR2 as well as that of TLR4, as determined by RT-PCR analysis (Fig. 5A) . Because LPS stimulates TLR2 and TLR4 gene expression in human endothelial cells (14) , we tested whether LPS and CD14 upregulate the expression of either TLR2 or TLR4 in mouse aortic SMC. LPS and CD14 had no effect on TLR4 mRNA levels but increased TLR2 mRNA expression eightfold in wild-type mouse aortic SMC (Fig. 5) . In contrast, LPS did not increase TLR2 expression in aortic SMC from C3H/HeJ mice that carry inactivating mutations of TLR4 (30, 33) , indicating that this effect is dependent on the presence of functional TLR4. Thus TLR4 activation markedly enhances TLR2 expression, suggestive of "cross-talk" between TLR2 and TLR4 in mouse VSMC.
LPS-induced ERK1/2 activation in mouse aortic SMC is TLR4 and CD14 dependent. LPS alone only weakly activated ERK1/2 in passage 5 aortic SMC, and exogenous CD14 had no effect when added alone but markedly stimulated ERK1/2 when added together with LPS (Fig. 6A) . In contrast, LPS alone activated ERK1/2 in passage 3 mouse aortic SMC, and exogenous CD14 exhibited only a minimal costimulatory effect with LPS (Fig. 6E) . Therefore, even though lower-passage SMC may not require exogenous CD14 for efficient LPSinduced TLR4 activation, we used costimulation with CD14 plus LPS to consistently activate TLR4 in subcultured mouse aortic SMC. As in human VSMC, stimulation with LPS and CD14 induced an increase in the levels of phospho-ERK1/2 in SMC expressing wild-type TLR4 (Fig. 6A) but did not affect the levels of phospho-ERK1/2 in TLR4 signaling-deficient SMC (Fig. 6B ). LPS and CD14 likewise activated ERK1/2 in SMC from wild-type C57BL/6 mice ( Fig. 6C ) and in SMC from TLR2Ϫ/Ϫ mice (Fig. 6D) , indicating an essential role of TLR4, but not of TLR2, in LPS-induced ERK1/2 activation.
LPS-induced MCP-1 release and NF-B activity in mouse aortic SMC require TLR4.
We also tested the role of TLR4 versus TLR2 in LPS-induced MCP-1 release and NF-B activation in mouse VSMC. Exposure to LPS and CD14 for 6 h stimulated MCP-1 release by 33-fold in aortic SMC derived from wild-type mice but did not affect MCP-1 release in TLR4 signaling-deficient SMC (Fig. 7A) . LPS and CD14 also markedly increased MCP-1 release in aortic SMC derived from either TLR2ϩ/ϩ or TLR2Ϫ/Ϫ mice (8-and 11-fold, respectively), indicating that TLR4 is essential for LPS-induced MCP-1 release, whereas TLR2 is not. Aortic SMC derived from wild-type and TLR4 signaling-deficient mice were transfected with a NF-B-luciferase reporter plasmid and incubated for 6 h with or without LPS and CD14 (Fig. 7B) . LPS and CD14 exposure stimulated NF-B activity by fourfold in SMC from wild-type mice but did not affect NF-B activity in SMC from TLR4 mutant mice. The time dependence of LPS and CD14-induced NF-B activation was compared in aortic SMC from TLR2ϩ/ϩ and TLR2Ϫ/Ϫ mice by EMSA analysis (Fig.  7B) . The nuclear level of NF-B was maximal 1 h after exposure to LPS and CD14 and was similar in TLR2ϩ/ϩ and TLR2Ϫ/Ϫ SMC. Nuclear NF-B remained elevated after 24 h in both cell types. Together the results provide strong evidence that LPS stimulates MCP-1 and activates NF-B by acting via TLR4 in mouse aortic SMC. 
DISCUSSION
These findings support the hypothesis that activation of TLR4 signaling promotes a proinflammatory phenotype in human and mouse arterial SMC, characterized by production of IL-1␣, IL-6, and MCP-1. To probe the role of TLR4, we used E. coli LPS, the prototypical TLR4 agonist. The role of TLR4 in LPS signaling in human arterial SMC was clearly demonstrated by the marked inhibition of LPS-induced MCP-1 release and ERK1/2 activation by expression of dominant negative TLR4. Aortic SMC derived from TLR signalingdeficient mice were used to further address the mechanisms of LPS action. LPS also induced MCP-1 release, ERK1/2 activation, and NF-B activation in SMC derived from wild-type or TLR2-deficient mice but failed to do so in SMC from TLR4 signaling-deficient mice, further documenting the essential role of TLR4, rather than TLR2, in LPS signaling in VSMC.
Mouse aortic SMC were found to express TLR2 mRNA constitutively, in contrast with human arterial SMC that did not, indicating that significant differences exist in the TLR biology of VSMC from these two species. Furthermore, TLR2 mRNA levels were markedly increased by LPS in wild-type mice but not in TLR4 signaling-deficient mouse aortic SMC, strongly suggesting that TLR4 mediates this upregulation. Stimulation by LPS causes increased TLR2 expression in other cell types, including mouse macrophages, human monocytes, and human endothelial cells (14, 45) . The TLR4-dependent upregulation of TLR2 expression in VSMC may be an additional mechanism whereby LPS could promote vascular inflammation, rendering VSMC sensitive to additional classes of microbial and endogenous products and thereby amplifying proinflammatory responses.
MCP-1 is one member of a key group of chemokines thought to promote monocyte migration into the intima in response to hypercholesterolemia or vascular injury. The absence of either MCP-1 or its receptor reduces lesion formation and mononuclear phagocyte accumulation within the artery wall elicited by hypercholesterolemia or arterial injury in mice (6, 11, 16) , and inhibition of MCP-1 activity reduces injury-induced arterial inflammation in monkeys (11) . MCP-1 is also present in human atherosclerotic plaque, consistent with a role in the human disease process (28, 51) . In the present study, LPS was found to be a strong inducer of MCP-1 release by arterial SMC, confirming recent findings by others (38) . Furthermore, both intralesion levels of MCP-1 mRNA and lesion size are reduced in ApoEϪ/Ϫ mice that are also deficient in MyD88, a downstream mediator of IL-1 and TLR signaling (5, 26) , supporting a potential role of TLR-stimulated MCP-1 production in lesion formation in this model. The present findings raise the possibility that TLR4-induced MCP-1 release from VSMC may contribute to lesion formation in ApoEϪ/Ϫ mice.
The exquisite sensitivity of SMC to LPS supports the potential importance of SMC TLR4 in vascular pathology. Both Fig. 5 . Mouse aortic SMC express TLR2 and TLR4 mRNA, and LPS upregulates TLR2 expression. Aortic SMC from wild-type (WT) (A and B) and TLR4 mutant (B) mice were incubated with or without LPS and CD14 for 5 h, and total RNA was prepared. cDNAs were amplified for 30 cycles, and products were size separated by electrophoresis and stained with ethidium bromide (A). Relative TLR2 mRNA levels were determined by real-time RT-PCR (n ϭ 4 replicates/group). *P ϭ 0.001 vs. control SMC. human and mouse arterial SMC were activated by low levels of LPS (ng/ml), in agreement with two other studies with human VSMC (24, 38) , and thus display LPS sensitivity similar to that of macrophages (12) and endothelial cells (32) . In monocytes and macrophages, the ability of low levels of LPS to activate TLR4 requires the participation of the glycosylphosphatidylinositol-anchored cell surface protein CD14 and MD-2, a secreted glycoprotein that binds to the ectodomain of TLR4, Fig. 6 . LPS activates ERK1/2 in aortic SMC from wild-type and TLR2Ϫ/Ϫ mice but not SMC from TLR4 mutant mice. Mouse aortic SMC were deprived of serum, incubated for 30 min with or without CD14 (100 ng/ml) or LPS (A-D: 100 ng/ml; E: 10 or 100 ng/ml), and analyzed for pERK1/2 and total ERK1/2. SMC were derived from TLR4 wild-type (A and E), TLR4 signalingdeficient (B), TLR2ϩ/ϩ (C), and TLR2Ϫ/Ϫ (D) mice; P3 and P5 are passage 3 and passage 5, respectively. Fig. 7 . LPS stimulates MCP-1 release and NF-B activity in aortic SMC derived from wild-type and TLR2Ϫ/Ϫ but not TLR4 mutant mice. A: SMC were deprived of serum then incubated for 6 h in fresh media with or without LPS and CD14 (100 ng/ml each). MCP-1 levels were determined in cell supernatants (n ϭ 6 replicates/group). *P Ͻ 0.001 vs. control SMC. Results shown are representative of three independent experiments. B: SMC were transfected with NF-B-luciferase reporter plasmid, deprived of serum, and incubated 6 h with or without LPS and CD14. Luciferase activity was normalized relative to the level in control SMC. Results are means Ϯ SE of 15 replicates from three experiments. C: SMC were serum deprived and incubated with LPS and CD14 for 0 -24 h, and nuclear extracts were analyzed by EMSA. Addition of nonlabeled B oligonucleotide abolished binding of the labeled B probe, demonstrating specificity of the bands. *P Ͻ 0.001 vs. control SMC.
forming an active TLR4-MD-2 complex. CD14 is thought to enhance the transfer of LPS monomers to MD-2, whereas binding of LPS to MD-2 leads to TLR4 activation (18, 46) . In the present study, we found that human arterial SMC consistently express MD-2 mRNA at levels equivalent to or greater than those in human monocytes, suggesting that MD-2 contributes to their LPS responsiveness. Our findings also agree with a recent study that found that HCoASMC express CD14 and can respond to low levels of LPS in the absence of exogenous CD14 (38) . On the other hand, we found that HPASMC express only low levels of CD14 mRNA and do not express cell surface CD14. In addition, mouse aortic SMC were activated by LPS alone when studied at early passage but required a simultaneous addition of recombinant CD14 and LPS at later passage. Together, the results suggest that VSMC can express CD14 at levels sufficient to allow efficient activation of TLR4 by LPS, but there may be intrinsic differences in the levels of CD14 expression in SMC derived from arteries of different anatomic origins. Alternatively, it is possible that CD14 expression declines with repeated subculture, as reported in a study of human umbilical vein endothelial cells (19, 24) , a phenomenon that could conceivably vary among VSMC derived from anatomically distinct vessels. Further studies are required to distinguish between these possibilities.
The exquisite sensitivity of SMC to LPS also has important practical implications with respect to in vitro studies of SMC function. First, the present findings indicate that it is critical to culture SMC in media containing negligible levels of endotoxin, because even trace amounts of LPS may produce a baseline state that actually reflects substantial activation, confounding the results obtained. Second, it is important to consider the exquisite sensitivity of SMC to low LPS concentrations when interpreting studies in which SMC have been treated with putative ligands that have not been tested for the presence of LPS, such as recombinant proteins produced in bacteria. Hence, when recombinant proteins or other ligands elicit responses similar to those produced by LPS, it would be advisable to verify that the observed effect is not mediated by contaminating endotoxin.
The present findings support the possibility that bacterial or host-derived products present in the artery wall may promote inflammation in part by direct activation of TLR4 expressed in VSMC. For example, C. pneumoniae is frequently found in atherosclerotic lesions (22, 25) , and C. pneumoniae can activate VSMC and dendritic cells via mechanisms that are at least partially dependent on TLR4 (31, 36) and may involve the TLR4-dependent effects of chlamydial heat shock protein (HSP) 60 (7, 8, 36, 43) . TLR4 expressed by SMC may also be a target of putative endogenous host-derived ligands, including HSP60, HSP70, and degradation products of hyaluronan, which are present at elevated levels in atherosclerotic lesions relative to those in normal arteries (3, 13, 29, 42, 44, 48) . Therefore, it is possible that either microbial or host-derived products might activate TLR4 expressed by VSMC to promote inflammation in the vessel wall during atherogenesis. Investigating these possibilities will likely be a significant focus of future research.
In humans, a possible link between TLR4 polymorphisms and the development of atherosclerosis has been proposed, although existing data remain controversial. Expression of the Asp299Gly allele was associated with a reduced progression of atherosclerosis and intima-media thickness in the common carotid artery (20) and a reduced risk of acute coronary events (1) . However, other studies (4, 49) found that this TLR4 polymorphism was not associated with the presence of carotid or coronary stenosis. Thus whether or not TLR4 polymorphisms are linked to the risk of atherosclerosis remains to be determined.
During the last three decades, considerable interest has arisen in the potential pathogenic role of microbes in atherogenesis, based in part on evidence that bacterial and viral products are present in some atherosclerotic lesions. Chronic infections may promote atherosclerosis via multiple mechanisms, including direct effects of microbial products on circulating leukocytes and endothelial cells. In turn, SMC may respond to inflammatory mediators released by endothelial cells or macrophages resident within the vascular wall. The present findings suggest that TLR4-dependent activation of SMC is an additional pathway that may contribute to the atherogenic process. In this context, it will be critical to determine whether TLR4 ligands, derived either from the host or from microbial pathogens, are present in vascular lesions where they could directly induce a proinflammatory phenotype in VSMC.
